1 August 2012 - MAP Pharmaceuticals Inc (Nasdaq: MAPP), a biopharmaceutical company focused on developing and commercialising new therapies to address patient needs in neurology, has announced today that it is planning to offer and sell shares of its common stock in an underwritten public offering.<...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up